Last reviewed · How we verify
NCT05708209
The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124
trial in Oral Squamous Cell Carcinoma in 40 participants. Completed in 1 January 2023.
1 December 2022
Quick facts
| Lead sponsor | Fayoum University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 November 2022 |
| Primary completion | 1 December 2022 |
| Estimated completion | 1 January 2023 |
| Sites | 1 location across Egypt |
Conditions studied
- Oral Squamous Cell Carcinoma — all drugs for Oral Squamous Cell Carcinoma →
Sponsor
Fayoum University
Who can join
Adults 20 to 65, any sex, with Oral Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objective: is to determine the diagnostic accuracy of lncRNA MALAT1 as a potential salivary biomarker of OSCC as well as assessment of the salivary expression level of miRNA 124 which is targeted by MALAT1. Materials and Methods: Saliva Samples were collected for the quantitative determination of salivary "MALAT1 and mi RNA -124" using quantitative Real-time Polymerase Chain Reaction technique for the two study groups, Group A: 20 patients with a diagnosis suggestive of OSCC and Group B: 20 age-and-sex-matched healthy individuals, as normal controls.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Gender Differences and miRNAs Expression in Cancer: Implications on Prognosis and Susceptibility.
Caserta S, Gangemi S, Murdaca G, Allegra A. · · 2023 · cited 16× · PMID 37511303 · DOI 10.3390/ijms241411544 -
Non-Coding RNAs in Oral Cancer: Emerging Roles and Clinical Applications.
Dey S, Biswas B, Manoj Appadan A, Shah J, et al · · 2023 · cited 15× · PMID 37568568 · DOI 10.3390/cancers15153752 -
MALAT1 as a molecular driver of tumor progression, immune evasion, and resistance to therapy.
Bitaraf A, Zafarani A, Jahandideh P, Hakak-Zargar B, et al · · 2025 · cited 11× · PMID 41053822 · DOI 10.1186/s12943-025-02415-6 -
Long non-coding RNAs in ferroptosis, pyroptosis and necroptosis: from functions to clinical implications in cancer therapy.
Huang K, Yu L, Lu D, Zhu Z, et al · · 2024 · cited 10× · PMID 39267831 · DOI 10.3389/fonc.2024.1437698 -
Non-coding RNAs in oral cancer: Emerging biomarkers and therapeutic frontier.
Hashemi M, Khoushab S, Aghmiuni MH, Anaraki SN, et al · · 2024 · cited 9× · PMID 39583806 · DOI 10.1016/j.heliyon.2024.e40096 -
Investigating the role of exosomal long non-coding RNAs in drug resistance within female reproductive system cancers.
Shirani N, Abdi N, Chehelgerdi M, Yaghoobi H, et al · · 2025 · cited 8× · PMID 39925739 · DOI 10.3389/fcell.2025.1485422 -
Novel insights on oral squamous cell carcinoma management using long non-coding RNAs.
Sur S, Davray D, Basu S, Kheur S, et al · · 2024 · cited 8× · PMID 39308526 · DOI 10.32604/or.2024.052120 -
LncRNA MALAT1 in Keratinocyte function: A review of recent advances.
Juárez-Vicuña Y, Ruiz-Ojeda D, González-Ramírez J, Flores-Balderas X, et al · · 2024 · cited 8× · PMID 38532797 · DOI 10.1016/j.ncrna.2024.01.021
Verify or expand the search:
- PubMed search for NCT05708209
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oral Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT07063212 — A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) · Phase 2 · recruiting
- NCT06627270 — Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer · Phase 2 · recruiting
- NCT06055868 — People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity · recruiting
- NCT06321003 — SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography · recruiting
- NCT06258811 — Neoadjuvant Immunochemotherapy for LAOSCC · Phase 3 · recruiting
Other Fayoum University trials
Trials by the same sponsor.
- NCT07536620 — Metformin and Alveolar Cleft · Phase 2 · not yet recruiting
- NCT07444970 — Comparative Evaluation of Xenograft Alone and Sticky Bone in Sinus Lift With Concurrent Implant Placement · NA · not yet recruiting
- NCT07394179 — Transforming Channel Osteotomy Into Tunnel Osteotomy in Zygomatic Implant Preparation · NA · not yet recruiting
- NCT07277348 — Analysis of The Outcomes of Therapeutic Photorefractive Keratectomy Combined With Prophylactic Accelerated Cross-Linking · NA · not yet recruiting
- NCT07330726 — Lidocaine Patch and Lower Third Molar · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05708209 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fayoum University
- Last refreshed: 13 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05708209.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing